Hepatitis C virus infection and tobacco smoking - joint health effects and implications for treatment of both: A systematic review
Preprint
Abstract
Summary: Background: Tobacco smoking and hepatitis C virus (HCV) infection cause many diseases independently. The interaction of these conditions on health effects has not been widely studied. There is a paucity of information on addressing tobacco smoking in HCV treatment settings. This review examines the relationship between tobacco smoking and HCV infection and health outcomes and discusses opportunities for treating both conditions. Methods: A systematic review was conducted following the PRISMA 2009 guidelines (Registration No.: CRD42019127771) . We searched PubMed, EMBASE, Web of Science, and CINAHL on the health effects of tobacco smoking and HCV infection using keywords and MeSH terms for hepatitis C, tobacco smoking, hepatocellular carcinoma (HCC), chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), cardiovascular diseases (CVD), and chronic kidney disease (CKD). We used the Newcastle-Ottawa Scale, a measurement tool to assess systematic reviews (AMSTAR-2), and international narrative systematic assessment (INSA) tools to assess the methodological quality of the included studies. Findings: Tobacco smoking and HCV infection share similar underlying risk factors and hence it is unsurprising that tobacco smoking prevalence is higher in people living with HCV (PLHCV) than in the general population. Tobacco smoking and HCV infection have additive or multiplicative interaction to cause HCC, COPD, DM, CVD, and CKD. Anti-HCV direct-acting antiviral (DAA) treatment is highly efficacious and widely accessible in many countries, but untreated tobacco smoking addiction may undermine the achievement of optimal health outcomes possible from HCV treatment. Interpretation: The scale-up of DAA treatment programs globally is an opportunity to address the high prevalence of tobacco smoking in PLHCV by concurrently offering tobacco smoking cessation treatment. Simultaneous initiation of smoking cessation therapy at HCV treatment centres is likely to be cost-effective at maximizing the health gains afforded by DAA treatment. Studies are needed to evaluate the effect of tobacco smoking cessation on the sustained virologic response in DAA treated patients.Keywords
This publication has 66 references indexed in Scilit:
- Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis CHepatology, 2012
- Seronegative Hepatitis C Virus Infection in a Child Infected via Mother-to-Child TransmissionJournal of Clinical Microbiology, 2012
- Hepatocellular Carcinoma Risk Factors and Disease Burden in a European Cohort: A Nested Case-Control StudyJNCI: Journal of the National Cancer Institute, 2011
- Prevalence of Tobacco Use and Association between Cardiometabolic Risk Factors and Cigarette Smoking in Youth with Type 1 or Type 2 Diabetes MellitusThe Journal of Pediatrics, 2011
- Chronic Hepatitis C Virus Infection is Associated with More Severe AsthmaAllergology International, 2011
- Hepatitis C infection and risk of diabetes: A systematic review and meta-analysisJournal of Hepatology, 2008
- Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: Case‐control studyInternational Journal of Cancer, 2008
- Current Approaches to HCV Infection in Current and Former Injection Drug UsersJournal of Addictive Diseases, 2008
- Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus‐infected and hepatitis C virus‐cleared patientsLiver International, 2008
- Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysisJournal of Hepatology, 2006